Cryoport, an Irvine, California-headquartered cryogenic logistics company, has agreed to support TiGenix, a ‎Leuven, Belgium-headquartered biopharmaceutical company developing stem-cell therapies, as it conducts a Phase Ib/IIa clinical study to evaluate expanded allogeneic adipose‐derived stem cells for treating sepsis.

Under the agreement, Cryoport will provide global logistics support for transporting cryogenically preserved clinical commodities.

TiGenix aims to recruit 180 patients in at least 50 centers for the randomized double-blind placebo controlled study. Specifically, the study will evaluate the therapy for treating sepsis in adult patients with severe community‐acquired bacterial pneumonia and admitted to the intensive care unit.

Source: Cryoport